<DOC>
	<DOCNO>NCT02137161</DOCNO>
	<brief_summary>OBJECTIVE To evaluate efficacy bromfenac ophthalmic solution 0.09 % reduce postoperative inflammation eye pseudoexfoliation syndrome ( PEX ) undergo cataract surgery receive standard postoperative eye drop ( dexamethasone 0.1 % plus tobramycin 0.3 % ophthalmic solution ) . DESIGN Two arm , parallel group , randomize , single center , prospective , phase IV clinical trial . PARTICIPANTS Sixty-two subject PEX cataract sequentially assign , accord computer-generated randomization list ( 1:1 ) , bromfenac ( n = 31 ) ( n = 31 ) . INTERVENTION Cataract surgery mean phacoemulsification implantation posterior-chamber intraocular lens perform two experienced ophthalmic surgeon . Standard Arm : standard antibiotic steroid ophthalmic suspension give start day surgery two week , dose QID first week BID second week ( dexamethasone 0.1 % tobramycin 0.3 % eye drop association ) . Experimental Arm : eye receive bromfenac BID two week start day surgery . Standard post-operative topical antibiotic steroid also give concurrently , dose QID first week BID second week ( dexamethasone 0.1 % tobramycin 0.3 % eye drop association ) . Measurements carry baseline one day , 3 day , 1 week 4 week cataract extraction .</brief_summary>
	<brief_title>Bromfenac Reduce Inflammation Patients With Pseudoexfoliation Syndrome After Cataract Surgery</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Cataract</mesh_term>
	<mesh_term>Exfoliation Syndrome</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Bromfenac</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Tobramycin</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<mesh_term>Tetrahydrozoline</mesh_term>
	<criteria>cataract pseudoexfoliation syndrome history ocular inflammation trauma previous intraocular surgery corneal haze retinal vascular disease diabetic retinopathy variation foveal profile OCT ( macular edema , epiretinal membrane ) moderate severe age relate macular degeneration</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>